The Manufacturers Life Insurance Company Sells 7,011 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

The Manufacturers Life Insurance Company reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 6.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 108,548 shares of the medical equipment provider's stock after selling 7,011 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.16% of Lantheus worth $8,715,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. lifted its stake in shares of Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 247 shares during the period. GAMMA Investing LLC lifted its position in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 208 shares during the period. Fidelis Capital Partners LLC bought a new stake in shares of Lantheus during the 1st quarter valued at $34,000. FinTrust Capital Advisors LLC grew its position in shares of Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock worth $41,000 after buying an additional 232 shares during the period. Finally, Nkcfo LLC bought a new position in shares of Lantheus in the 2nd quarter worth about $47,000. 99.06% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Gerard Ber sold 15,500 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company's stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,852 shares of company stock valued at $3,922,001. Company insiders own 1.50% of the company's stock.

Lantheus Stock Up 1.1 %

Shares of LNTH stock traded up $1.22 during mid-day trading on Friday, hitting $107.79. The company's stock had a trading volume of 296,412 shares, compared to its average volume of 997,925. The stock has a market cap of $7.47 billion, a price-to-earnings ratio of 16.46 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The business has a 50-day moving average price of $103.77 and a 200 day moving average price of $87.35.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. During the same period last year, the firm posted $1.40 EPS. Lantheus's quarterly revenue was up 22.5% compared to the same quarter last year. Research analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on LNTH. Leerink Partners boosted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. JMP Securities cut their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Redburn Atlantic started coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. Finally, Truist Financial reduced their price target on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.